A double-blind study, in the New England Journal of Medicine, found that the addition of aliskiren to standard therapy in patients with Type 2 diabetes is not supported and may even be harmful.
http://www.ivanhoe.com/channels/p_channelstory.cfm?storyid=30443
http://en.wikipedia.org/wiki/Aliskiren
http://www.ivanhoe.com/channels/p_channelstory.cfm?storyid=30443
http://en.wikipedia.org/wiki/Aliskiren